Next-generation influenza vaccines could save millions of lives, finds WHO

Next-generation influenza vaccines that provide broader and longer-lasting protection than current seasonal shots could dramatically reduce the global impact of influenza, according to a new assessment by the World Health Organization (WHO). The report, titled the Full Value of Improved Influenza Vaccines Assessment (FVIVA) and published alongside a supplement in the journal Vaccine, evaluates the health, economic, and policy implications of improved and universal influenza vaccines.

📊 The Global Influenza Burden

Seasonal influenza affects nearly one billion people annually, with 3–5 million severe cases and 290,000–650,000 deaths due to respiratory complications. Although existing vaccines reduce disease burden, their effectiveness varies by season and population group, and protection typically lasts for only one flu season. Vaccine access also remains unequal, with upper-middle and high-income countries consuming the majority of doses.

🚀 The Promise of Next-Generation Vaccines

According to the FVIVA projections, widespread use of improved or universal influenza vaccines between 2025 and 2050 could:

• Prevent up to 18 billion influenza cases

• Save up to 6.2 million lives

• Protect high-risk populations including older adults, young children, and pregnant women

These vaccines aim to provide broader strain coverage, longer duration of immunity, and stronger protection against severe disease — reducing the need for frequent reformulation.

💊 Combating Antimicrobial Resistance

Beyond preventing infections, next-generation vaccines could significantly reduce antibiotic misuse. Current influenza vaccination already prevents an estimated 10 million unnecessary antibiotic doses annually. Improved vaccines could avert up to 1.3 billion defined daily doses of antibiotics by 2050, helping curb global antimicrobial resistance.

🌐 Policy, Access & Future Development

The FVIVA framework supports governments, researchers, and manufacturers in making evidence-based decisions about vaccine investment and rollout. Adoption will depend on national disease burden, cost-effectiveness, pricing, safety, duration of protection, and suitability for low- and middle-income countries.

In alignment with WHO’s Global Influenza Strategy 2019–2030, updated Preferred Product Characteristics (2025) emphasize broader protection, improved safety, temperature stability, and technology transfer to support local manufacturing capacity.

As of February 2026, 46 next-generation influenza vaccines are in clinical development across diverse technology platforms, reflecting growing global momentum.